A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER
Open accessAbstract
INTRODUCTION: ) mutation. METHODS: oncogene, who progressed after platinum-based chemotherapy and 1 additional therapy (could include immune checkpoint inhibitor therapy). Randomized patients (3:2) received either 200 mg abemaciclib twice daily or 150 mg erlotinib once daily with best supportive care until disease progression or unacceptable toxicity. The primary endpoint was overall survival (OS); secondary endpoints included overall response rate (ORR), progression-free survival (PFS), and safety. RESULTS: Between December 2014 and April 2017, 453 patients were randomly assigned to receive abemaciclib (N = 270) or erlotinib (N = 183). Median OS was 7.4 months (95% confidence interval [CI]: 6.5, 8.8) with abemaciclib and 7.8 months (95% CI: 6.4, 9.5) with erlotinib (hazard ratio [HR] = 0.968 [95% CI: 0.768, 1.219]; p = .77). Median PFS was 3.6 months (95% CI: 2.8, 3.8) with abemaciclib and 1.9 months (95% CI: 1.9, 2.0) with erlotinib (HR = 0.583 [95% CI: 0.470, 0.723]; p <.000001). ORR was 8.9% and 2.7% (p = .010), and the disease control rate was 54.4% and 31.7% (p <.001) with abemaciclib and erlotinib, respectively. Safety results reflected the known safety profiles of abemaciclib and erlotinib. CONCLUSIONS: In this study, the primary endpoint of OS was not met; PFS and ORR were improved with manageable toxicity in the abemaciclib arm. The increases in response rates and PFS support further investigation of abemaciclib in other NSCLC subpopulations or in combination with other agents. CLINICAL TRIAL REGISTRATION: www.ClinicalTrials.gov, identifier: NCT02152631.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In JUNIPER, the erlotinib-treated KRAS mutant advanced NSCLC cohort had an ORR of 2.7%.
“The cohort treated with erlotinib experienced lower values, including a PFS of 1.9 months, an ORR of 2.7%, and a DCR of 31.7%.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [62]
In JUNIPER, the erlotinib-treated KRAS mutant advanced NSCLC cohort had a DCR of 31.7%.
“The cohort treated with erlotinib experienced lower values, including a PFS of 1.9 months, an ORR of 2.7%, and a DCR of 31.7%.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [62]
The PFS, ORR, and DCR differences favoring abemaciclib were statistically significant, demonstrating clinical activity of CDK4/6 inhibition in KRAS exon 12 and exon 13 NSCLC.
“These latter three values were statistically significant, demonstrating clinical activity of CDK4/6 inhibition within KRAS exon 12 and exon 13 NSCLC patients62.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [62]
In JUNIPER, the abemaciclib-treated KRAS mutant advanced NSCLC cohort had an ORR of 8.9%.
“The cohort treated with abemaciclib experienced a PFS of 3.6 months, an ORR of 8.9%, and a DCR of 54.4%.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [62]
In JUNIPER, the erlotinib-treated KRAS mutant advanced NSCLC cohort had a PFS of 1.9 months.
“The cohort treated with erlotinib experienced lower values, including a PFS of 1.9 months, an ORR of 2.7%, and a DCR of 31.7%.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [62]
In JUNIPER, the abemaciclib-treated KRAS mutant advanced NSCLC cohort had a DCR of 54.4%.
“The cohort treated with abemaciclib experienced a PFS of 3.6 months, an ORR of 8.9%, and a DCR of 54.4%.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [62]
In JUNIPER, the abemaciclib-treated KRAS mutant advanced NSCLC cohort had a PFS of 3.6 months.
“The cohort treated with abemaciclib experienced a PFS of 3.6 months, an ORR of 8.9%, and a DCR of 54.4%.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [62]
In JUNIPER, median OS was similar between abemaciclib and erlotinib in KRAS mutant advanced NSCLC, and the difference was statistically insignificant.
“The outcome showed a similar median OS between the two therapies, which was statistically insignificant.”
From Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes (2021) · cites this paper as [62]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · see citing works
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724 · see citing works
<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641 · cited 2× · see citing works
“The KRAS+TP53 and KRAS-only tumors (lack TP53 or STK11 co-mutations) are more sensitive to PD-1/programmed deathligand 1 (PD-L1) inhibitors, while KRAS+STK11 are least sensitive (26).”
BackgroundSkoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936 · see citing works
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743 · see citing works
Self-citationLinardou, H., Dahabreh, I. J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Papadimitriou, C. A., & Murray, S. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70206-7 · Cited by 739 · see citing works
Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Dieras, V. C., Patt, D. A., Wildiers, H. P. M. W., Hudis, C. A., O’Shaughnessy, J., Zamora, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0754 · Cited by 683 · see citing works
Zhu, C.-Q., da Cunha Santos, G., Ding, K., Sakurada, A., Cutz, J.-C., Liu, N., Zhang, T., Marrano, P., Whitehead, M., Squire, J. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8924 · Cited by 661 · see citing works
Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577 · see citing works
Garassino, M. C., Martelli, O., Broggini, M., Farina, G., Veronese, S., Rulli, E., Bianchi, F., Bettini, A., Longo, F., Moscetti, L., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70310-3 · Cited by 475 · see citing works
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415 · see citing works
Ciuleanu, T., Stelmakh, L., Cicenas, S., Miliauskas, S., Grigorescu, A. C., Hillenbach, C., Johannsdottir, H. K., Klughammer, B., & Gonzalez, E. E. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70385-0 · Cited by 374 · see citing works
Jänne, P. A., van den Heuvel, M. M., Barlesi, F., Cobo, M., Mazieres, J., Crinò, L., Orlov, S., Blackhall, F., Wolf, J., Garrido, P., et al. (2017) · JAMA · doi:10.1001/jama.2017.3438 · Cited by 335 · see citing works
Self-citationBrugger, W., Triller, N., Błasińska-Morawiec, M., Curescu, S., Sakalauskas, R., Manikhas, G. M., Mazières, J., Whittom, R., Ward, C., Mayne, K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8162 · Cited by 280 · see citing works
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
Scheffler, M., Ihle, M. A., Hein, R., Merkelbach-Bruse, S., Scheel, A. H., Siemanowski, J., Brägelmann, J., Kron, A., Abedpour, N., Ueckeroth, F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.013 · Cited by 264 · see citing works
Karachaliou, N., Mayo, C., Costa, C., Magrí, I., Giménez-Capitán, A. A., Molina‐Vila, M. Á., & Rosell, R. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.09.007 · Cited by 232 · see citing works
Fakih, M., O'Neil, B., Price, T. J., Falchook, G. S., Desai, J., Kuo, J., Govindan, R., Rasmussen, E., Morrow, P. K. H., Ngang, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.3003 · Cited by 172 · see citing works
Prognostic and Predictive Value in<i>KRAS</i>in Non–Small-Cell Lung Cancer: A Review
Wood, K., Hensing, T., Malik, R., & Salgia, R. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.0405 · Cited by 164 · see citing works
Kim, M. J., Shin, H. C., Shin, K. C., & Ro, J. Y. (2012) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2012.07.006 · Cited by 80 · see citing works
Cicėnas, S., Geater, S. L., Petrov, P., Hotko, Y., Hooper, G. J., Xia, F., Mudie, N. Y., & Wu, Y.-L. L. C. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.10.007 · Cited by 61 · see citing works
Zer, A., Ding, K., Lee, S. M., Goss, G. D., Seymour, L., Ellis, P. M., Hackshaw, A., Bradbury, P. A., Han, L., O’Callaghan, C. J., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.11.010 · Cited by 56 · see citing works
Stinchcombe, T. E., & Socinski, M. A. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31819516a6 · Cited by 52 · see citing works
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial
Rulli, E., Marabese, M., Torri, V., Farina, G., Veronese, S. M., Bettini, A., Longo, F., Moscetti, L. I., Ganzinelli, M., Lauricella, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv318 · Cited by 46 · see citing works
Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non-Small-Cell Lung Cancer.
Langer, C. J. (2011) · PubMed Central · Cited by 41 · see citing works
Second-Line Chemotherapy for Non–Small-Cell Lung Cancer: Recent Data with Pemetrexed
Hanna, N. H. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.s.007 · Cited by 14 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [24]Mirati Therapeutics, Inc Mirati therapeutics presents first clinical data of Phase 1/2 trial of MRTX849 At the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (2019). Available at: https://ir.mirati.com/news-releases/news-details/2019/Mirati-Therapeutics-Presents-First-Clinical-Data-Of-Phase-12-Trial-Of-MRTX849-At-The-2019-AACR-NCI-EORTC-International-Conference-On-Molecular-Targets-And-Cancer-Therapeutics/default.aspx (Accessed [Accessed September 1, 2020]).
Cited by
Sorted by citations
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 555 · see citing works
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 339 · see citing works
Drugging KRAS: Current perspectives and state-of-art review
Parikh, K., Banna, G., Liu, S. V., Friedlaender, A., Desai, A., Subbiah, V., & Addeo, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01375-4 · Cited by 164 · see citing works
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
Salgia, R., Pharaon, R. R., Mambetsariev, I., Nam, A., & Sattler, M. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100186 · Cited by 163 · see citing works
Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
Šutić, M., Vukić, A., Baranašić, J., Försti, A., Džubur, F., Samaržija, M., Jakopović, M., Brčić, L., & Knežević, J. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111102 · Cited by 130 · see citing works
Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials
Panagiotou, Ε., Gomatou, G., Trontzas, I. P., Syrigos, N. K., & Kotteas, E. A. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02688-5 · Cited by 76 · see citing works
Synthetic lethal strategies for the development of cancer therapeutics
Ngoi, N. Y. L., Gallo, D., Torrado, C., Nardo, M., Durocher, D., & Yap, T. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00966-z · Cited by 78 · see citing works
Palma, G., Khurshid, F., Lu, K., Woodward, B., & Husain, H. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00237-5 · Cited by 72 · see citing works
Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Désage, A.-L., Léonce, C., Swalduz, A., & Ortiz‐Cuaran, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.796832 · Cited by 60 · see citing works
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
Rebuzzi, S. E., Zullo, L., Rossi, G., Grassi, M., Murianni, V., Tagliamento, M., Prelaj, A., Coco, S., Longo, L., Bello, M. G. D., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052625 · Cited by 61 · see citing works
Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib
Wander, S. A., O’Brien, N. A., Litchfield, L. M., O’Dea, D., Guimaraes, C. M., Slamon, D. J., & Goel, S. (2022) · The Oncologist · doi:10.1093/oncolo/oyac138 · Cited by 49 · see citing works
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Scheiblecker, L., Kollmann, K., & Sexl, V. (2020) · Pharmaceuticals · doi:10.3390/ph13120418 · Cited by 47 · see citing works
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
Lindsay, C. R., Garassino, M. C., Nadal, E., Öhrling, K., Scheffler, M., & Mazières, J. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.07.005 · Cited by 45 · see citing works
Self-citationOvercoming KRAS-Mutant Lung Cancer
Luo, J., Ostrem, J. M. L., Pellini, B., Imbody, D., Stern, Y. E., Solanki, H. S., Haura, E. B., & Villaruz, L. C. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_360354 · Cited by 44 · see citing works
Lietman, C. D., Johnson, M. L., McCormick, F., & Lindsay, C. R. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351333 · Cited by 44 · see citing works
Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
Zhang, J., Xu, D., Zhou, Y., Zhu, Z.-F., & Yang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.676041 · Cited by 39 · see citing works
Cyclers’ kinases in cell division: from molecules to cancer therapy
Milletti, G., Colicchia, V., & Cecconi, F. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01196-z · Cited by 39 · see citing works
A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
Moreno, S., Bonfante, M., Zurek, E. E., Cherezov, D., Goldgof, D. B., Hall, L., & Schabath, M. B. (2021) · Tomography · doi:10.3390/tomography7020014 · Cited by 37 · see citing works
Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
Bteich, F., Mohammadi, M., Li, T., Bhat, M. A., Sofianidi, A. A., Wei, N., & Kuang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512030 · Cited by 32 · see citing works
KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
Ceddia, S., Landi, L. M., & Cappuzzo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169391 · Cited by 33 · see citing works
Cucurull, M., Notario, L., Sánchez‐Céspedes, M., Hierro, C., Estival, A., Carcereny, E., & Saigí, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.793121 · Cited by 33 · see citing works
Pujol, J.-L., Vansteenkiste, J., Rodríguez, L. P.-A., Gregorc, V., Mazières, J., Awad, M. M., Janne, P. A., Chisamore, M. J., Hossain, A. M., Chen, Y., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100234 · Cited by 27 · see citing works
Self-citationManolakos, P., & Ward, L. D. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13061010 · Cited by 27 · see citing works
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
Cekani, E., Epistolio, S., Dazio, G., Cefalì, M., Wannesson, L., Frattini, M., & Froesch, P. (2022) · Cancers · doi:10.3390/cancers14174103 · Cited by 26 · see citing works
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Torres-Jiménez, J., Espinar, J. B., Bote, H., Berjaga, M. Z., Esteban-Villarrubia, J., Fraile, J. Z., & Paz-Ares, L. G. (2024) · Drugs · doi:10.1007/s40265-024-02030-7 · Cited by 22 · see citing works
Self-citationPromising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer
Kaur, P., Singh, S. K., Mishra, M. K., Singh, S., & Singh, R. (2024) · Cancers · doi:10.3390/cancers16122205 · Cited by 19 · see citing works
Watson, N., Shatzel, J. J., & Al-Samkari, H. T. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2022.12.001 · Cited by 19 · see citing works
Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients
Jacobs, F., Cani, M., Malapelle, U., Novello, S., Napoli, V. M., & Bironzo, P. (2021) · Cancers · doi:10.3390/cancers13246332 · Cited by 17 · see citing works
Gao, S., Li, Y., He, Z., Zhu, J., Liang, D., Yang, S., Mo, J., Lam, K., Yu, X., Huang, M. S., et al. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2181338 · Cited by 13 · see citing works
Landscape of targeted therapies for lung squamous cell carcinoma
Chen, Q., Zheng, X.-S., Cheng, W., & Li, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1467898 · Cited by 12 · see citing works
Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
Sun, C., Talukder, M., Cao, D., & Chen, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.829759 · Cited by 12 · see citing works
Adagrasib: a novel inhibitor for KRAS G12C -mutated non-small-cell lung cancer
Guo, M. Z., Marrone, K. A., Spira, A. I., & Rosner, S. (2023) · Future Oncology · doi:10.2217/fon-2022-1106 · Cited by 9 · see citing works
Silva, D. D. E., Borba, G. B., Beal, J. R., Botrus, G., Osawa, A., Araújo, S. E. A., Moura, F., Kaliks, R. A., & Usón, P. L. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044209 · Cited by 7 · see citing works
Schneider, J. S., Khaled, N. B., Ye, L., Wimmer, R., Hammann, L., Weich, A., Suppan, C., Mahajan, U. M., Jung, A., Kumbrink, J., et al. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01080-7 · Cited by 5 · see citing works
The Dual Effects of CDK4/6 Inhibitors on Tumor Immunity
Si, Y., Li, H., & Shi, Y. (2025) · Cancers · doi:10.3390/cancers17243997 · Cited by 4 · see citing works
Ferrara, M. G., Stefani, A., Pilotto, S., Carbone, C., Vita, E., Salvatore, M. D., D’Argento, E., Sparagna, I., Monaca, F., Valente, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.792385 · Cited by 4 · see citing works
Gong, J., Hu, S., Shan, Q., Qin, J., Han, N., Xie, F., & Lu, H. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241239293 · Cited by 4 · see citing works
Hussein, S. A., Saadawy, A. H., Badr, E., Abdollah, M. R. A., Wael, N., Allam, R. M., Al-Abd, A. M., Sanchez, A. M. R., & Tolba, M. F. (2025) · Medical Oncology · doi:10.1007/s12032-025-02996-8 · Cited by 3 · see citing works
Patnaik, A., Hamilton, E. P., Xing, Y., Rasco, D. W., Smith, L. S., Lee, Y.-L., Fang, S., Wei, J., & Hui, A. (2022) · Cancers · doi:10.3390/cancers14204996 · Cited by 3 · see citing works
Raphael, A., Onn, A., Holtzman, L., Dudnik, J., Urban, D., Kian, W., Cohen, A. Y., Moskovitz, M. T., Zer, A., Bar, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.874712 · Cited by 3 · see citing works
Soon, Y. Y., Furnback, W. E., Kim, J., Chuang, P.-Y., Chavez, G. V., Proescholdt, C., & Koh, C. Y. C. (2023) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2023.100579 · Cited by 3 · see citing works
Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer
Karachaliou, A., Kotteas, E. A., Fiste, O., & Syrigos, K. (2024) · Cancers · doi:10.3390/cancers16081447 · Cited by 3 · see citing works
West, M. T., Kartika, T., Paquin, A. R., Liederbauer, E., Zheng, T. J., Lane, L., Thein, K. Z., & Shatzel, J. J. (2022) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100832 · Cited by 4 · see citing works
Melosky, B. L., Juergens, R. A., Banerji, S. O., Sacher, A. G., Wheatley‐Price, P., Snow, S. L., Tsao, M., Leighl, N. B., Martins, I., Cheema, P. K., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241308784 · Cited by 2 · see citing works
Liu, J., Wang, H., Aggarwal, A., Ortiz-Ruiz, M. J., Zapatero‐Solana, E., Lallena, M. J., Peregrina, S., del Hoyo, G. M., Velasco, S., Ebert, P. J., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1461530 · Cited by 2 · see citing works
Self-citationRui, M., Wang, Z., Fei, Z., Wu, Y., Wang, Y., Sun, L., Shang, Y., & Li, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.862640 · Cited by 2 · see citing works
Peng, S., Zhang, Y., Lin, X., Si, C., Van Horn, R. D., Dempsey, J. A., Goetz, E., Evans, R. J., Farber, A., Vandekopple, M. J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72650-y · Cited by 1 · see citing works
Lung Cancer and KRAS -Its Molecular Biology/Genetics and Therapeutic Strategy-
Koga, T., & Mitsudomi, T. (2022) · Haigan · doi:10.2482/haigan.62.188 · Cited by 1 · see citing works
New Insights on Success and Failed Drugs
Sun, Z., & Zhou, Y. (2024) · Springer eBooks · doi:10.1007/978-981-97-7274-2_10
Ren, S., Wang, W., Yao, X., Fang, W., Li, G., Feng, Y., & Xia, M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1511171
Sahebjam, S., Bazer, D. A., Rhun, É. L., Queirolo, P., Jérusalem, G., Johnston, E. L., & Conte, P. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdag005
Cardiovascular toxicity of cyclin-dependent kinase 4 and 6 inhibitors
Zhang, J., Ma, Z., Chen, P., Tian, L., Fang, F., & Li, J. (2025) · Journal of Cardio-oncology · doi:10.1097/co9.0000000000000007
Ku, Y., Zheng, Y., Ding, Y., Zhang, P., Wu, X., & Chen, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167119
- Authors
- Goldman, J. W., Mazieres, J., Barlesi, F., Dragnev, K. H., Koczywas, M., Göskel, T., Cortot, A. B., Girard, N., Wesseler, C., Bischoff, H., Nadal, E., Park, K., Lu, S., Taus, A., Cobo, M., Estrem, S. T., Wijayawardana, S. R., Turner, K., Oakley, G. J., Hurt, K. C., Chiang, A. Y., Hossain, A. M., John, W. J., & Paz-Ares, L.
- Affiliations
- University of California, Los Angeles (US)
- Dartmouth–Hitchcock Medical Center (US)
- City Of Hope National Medical Center (US)
- Ege University (TR)
- Université de Lille (FR)
- Hospices Civils de Lyon (FR)
- Asklepios Klinikum Harburg (DE)
- Institut Català d'Oncologia (ES)
- Samsung Medical Center (KR)
- Hospital Regional Universitario de Málaga (ES)
- Eli Lilly (United States) (US)
- Spanish National Cancer Research Centre (ES)
- Corresponding author
- Goldman, Jonathan W.
- ORCID
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-10-26
- Volume
- 10
- Pages
- 578756-578756
- ISSN
- 2234-943X (ISSN-L)
- PMC
- PMC7649422
- OpenAlex
- W3097340813
- Cited by
- 52
- References
- 26
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 7 · 2023: 8 · 2022: 15 · 2021: 11 · 2020: 1
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Repositori digital de la UPF (Universitat Pompeu Fabra) (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- abemaciclib, erlotinib, stage IV non-small cell lung cancer, KRAS mutation, CDK4/6 inhibitors, second-line therapy, platinum-refractory disease, progression-free survival, overall survival, overall response rate, drug safety, targeted therapy, immune checkpoint inhibitors, best supportive care, disease control rate, treatment toxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
